Latest Pharma Insights
Estée Lauder Marks One Year of ‘Beauty Reimagined’ With Expanded Distribution, Innovation
The Estee Lauder Companies' ‘Beauty Reimagined’ initiative is paying off a year after launch, with expanded distribution of brands and ‘breakthrough’ innovations, the firm says during a Feb. 5 fiscal second quarter earnings presentation.
HBW Insight - February 5, 2026
The Estee Lauder Companies' ‘Beauty Reimagined’ initiative is paying off a year after launch, with expanded distribution of brands and ‘breakthrough’ innovations, the firm says during a Feb. 5 fiscal second quarter earnings presentation.
HBW Insight - February 5, 2026
Bristol’s 2026 Revenue Buoyed By Eliquis Ahead Of Ex-US Generic Entries In 2027
The impact of rising demand, Medicare price negotiations under the IRA, Medicaid concessions under its Trump administration drug pricing deal and direct-to-patient sales will combine to boost Eliquis sales this year.
Scrip - February 5, 2026
The impact of rising demand, Medicare price negotiations under the IRA, Medicaid concessions under its Trump administration drug pricing deal and direct-to-patient sales will combine to boost Eliquis sales this year.
Scrip - February 5, 2026
J&J Unit Cerenovus Recalls Aneurysm Treatment Systems Following Patient Death
Cerenovus is recalling multiple products from its Cerepak Uniform, Cerepak Heliform and Cerepak Freeform product lines due to a higher-than-expected failure to detach rate. While customers were sent a safety alert in October, the US FDA announced the recall on Feb. 5.
Medtech Insight - February 5, 2026
Cerenovus is recalling multiple products from its Cerepak Uniform, Cerepak Heliform and Cerepak Freeform product lines due to a higher-than-expected failure to detach rate. While customers were sent a safety alert in October, the US FDA announced the recall on Feb. 5.
Medtech Insight - February 5, 2026
Lilly Takes Incretins Beyond Metabolic Diseases Amid Broader Development Push
The drugmaker highlighted a wide array of development programs in its fourth quarter earnings, including moving tirzepatide into multiple inflammatory conditions.
Scrip - February 5, 2026
The drugmaker highlighted a wide array of development programs in its fourth quarter earnings, including moving tirzepatide into multiple inflammatory conditions.
Scrip - February 5, 2026
In Latest Blow To Novo, Hims & Hers Launches Compounded Wegovy Pill
Novo Nordisk said it will take legal action against mass compounding of the new oral semaglutide formulation by Hims & Hers.
Scrip - February 5, 2026
Novo Nordisk said it will take legal action against mass compounding of the new oral semaglutide formulation by Hims & Hers.
Scrip - February 5, 2026
AstraZeneca’s Precision Oncology Approach Applies To Deal, Portfolio Decisions
Given its already large cancer drug pipeline, EVP of oncology R&D Susan Galbraith spoke with Scrip about how AstraZeneca is making precise choices about deals and development programs.
Scrip - February 5, 2026
Given its already large cancer drug pipeline, EVP of oncology R&D Susan Galbraith spoke with Scrip about how AstraZeneca is making precise choices about deals and development programs.
Scrip - February 5, 2026
Executives On The Move: Lexeo Therapeutics Gets A New CMO From Bristol Myers Squibb
Recent moves in the industry include internal moves at Immunocore, Ipsen and Merck KGaA, plus BioNTech gets a new chief people officer.
Scrip - February 5, 2026
Recent moves in the industry include internal moves at Immunocore, Ipsen and Merck KGaA, plus BioNTech gets a new chief people officer.
Scrip - February 5, 2026
The Hunt For A Monthly Obesity Drug Is Heating Up
Monthly obesity therapies may not have to rival the efficacy of weekly injections if they can be more convenient and help patients stay on treatment longer.
Scrip - February 5, 2026
Monthly obesity therapies may not have to rival the efficacy of weekly injections if they can be more convenient and help patients stay on treatment longer.
Scrip - February 5, 2026
Bayer Buoyant As Asundexian Shows 26% Reduction In Stroke
The co-principal investigator of OCEANIC-STROKE tells Scrip that the oral Factor XIa inhibitor could be paradigm-changing.
Scrip - February 5, 2026
The co-principal investigator of OCEANIC-STROKE tells Scrip that the oral Factor XIa inhibitor could be paradigm-changing.
Scrip - February 5, 2026
Roche Diagnostics Sees China Pricing Headwinds Easing In 2026 As Margins Recover From 2025 Lows
Besides China pricing reforms, Roche continued to face cost pressures linked to investments in new technologies such as CGM and LumiraDx. Tariffs also weighed on performance.
Medtech Insight - February 5, 2026
Besides China pricing reforms, Roche continued to face cost pressures linked to investments in new technologies such as CGM and LumiraDx. Tariffs also weighed on performance.
Medtech Insight - February 5, 2026
Strides Pharma: US-Led Global Fund Cut Hurts; Greater Focus On Ex-US Markets
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors.
Generics Bulletin - February 5, 2026
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors.
Generics Bulletin - February 5, 2026
Consumer Health And Wellness Market Outlook: What Trends Will Impact Self-Care In 2026?
In contributed commentary, Susan Levy, SBL Consulting Group founder and principal, discusses likely health and wellness market developments which would reflect a steady shift toward more accessible, consumer-centric models of care complementing traditional healthcare.
HBW Insight - February 5, 2026
In contributed commentary, Susan Levy, SBL Consulting Group founder and principal, discusses likely health and wellness market developments which would reflect a steady shift toward more accessible, consumer-centric models of care complementing traditional healthcare.
HBW Insight - February 5, 2026
Valbiotis Enters Women’s Health Arena With Menopause Supplement
French firm's new supplement combines seven ingredients to offer relief from common menopause symptoms.
HBW Insight - February 5, 2026
French firm's new supplement combines seven ingredients to offer relief from common menopause symptoms.
HBW Insight - February 5, 2026
US FDA’s Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
HBW Insight - February 5, 2026
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
HBW Insight - February 5, 2026
CDRH Highlights Harmonization Progress In International Assessment Report
The US FDA has published its annual international harmonization assessment for fiscal 2025, which reports on the device center’s progress in aligning medical device regulations with global standards to improve patient access to safe, innovative technologies.
Medtech Insight - February 5, 2026
The US FDA has published its annual international harmonization assessment for fiscal 2025, which reports on the device center’s progress in aligning medical device regulations with global standards to improve patient access to safe, innovative technologies.
Medtech Insight - February 5, 2026
Execs On The Move: January 26–30, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 5, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 5, 2026
Midi Health Gains Unicorn Status With $100M Funding Round; Adds Serena Ventures, Foresite Capital
Women’s health start-up Midi Health has raised $100m in a Series D financing, led by Goodwater Capital with new investors Foresite Capital and Serena Ventures. Midi, which focuses on women in midlife, said the money will support the next phase of growth.
Medtech Insight - February 5, 2026
Women’s health start-up Midi Health has raised $100m in a Series D financing, led by Goodwater Capital with new investors Foresite Capital and Serena Ventures. Midi, which focuses on women in midlife, said the money will support the next phase of growth.
Medtech Insight - February 5, 2026
Kashiv Biosciences Expands Latin American Footprint Through Saya Biologics Partnership
A biosimilar collaboration between Kashiv and Saya aims to expand access to affordable supportive oncology therapies in Mexico and 10 additional Central America and Caribbean markets.
Generics Bulletin - February 5, 2026
A biosimilar collaboration between Kashiv and Saya aims to expand access to affordable supportive oncology therapies in Mexico and 10 additional Central America and Caribbean markets.
Generics Bulletin - February 5, 2026
Krka Doubles Down On Vertical Integration With €140m Investment Push
Slovenia’s Krka is ramping up capital spending to expand global manufacturing capacity, betting that industrial scale and supply resilience will drive its next phase of growth.
Generics Bulletin - February 5, 2026
Slovenia’s Krka is ramping up capital spending to expand global manufacturing capacity, betting that industrial scale and supply resilience will drive its next phase of growth.
Generics Bulletin - February 5, 2026
Amgen Benefits From US Biosimilar Monopoly With $700m Sales For Pavblu
Amgen has revealed just how significant its first-mover advantage on biosimilar aflibercept has been in the US, with the firm’s Eylea rival bringing in sales of $700m in 2025 and helping to push Amgen’s annual biosimilars turnover up by more than a third to $3bn.
Generics Bulletin - February 5, 2026
Amgen has revealed just how significant its first-mover advantage on biosimilar aflibercept has been in the US, with the firm’s Eylea rival bringing in sales of $700m in 2025 and helping to push Amgen’s annual biosimilars turnover up by more than a third to $3bn.
Generics Bulletin - February 5, 2026
APAC Regulatory Update: Prevention, Access and Digital Integration Define Regional Momentum
Featuring: Prevention?driven reforms in Vietnam; surging demand for OTC and herbal based interventions in China; Singapore updates its health data infrastructure; regional regulatory harmonization across Australia, Singapore and Indonesia; and WHO sets formal direction for TCIM.
HBW Insight - February 5, 2026
Featuring: Prevention?driven reforms in Vietnam; surging demand for OTC and herbal based interventions in China; Singapore updates its health data infrastructure; regional regulatory harmonization across Australia, Singapore and Indonesia; and WHO sets formal direction for TCIM.
HBW Insight - February 5, 2026
Everest Bags APAC Rights To Micot’s First-In-Class Peptide
Everest Medicine obtains selected commercialization rights to first-in-class, Phase III stage bispecific peptide MT1013 from Shanxi Micot Technology at home. A trial for secondary hyperparathyroidism is due to be completed by year-end in China.
Scrip - February 5, 2026
Everest Medicine obtains selected commercialization rights to first-in-class, Phase III stage bispecific peptide MT1013 from Shanxi Micot Technology at home. A trial for secondary hyperparathyroidism is due to be completed by year-end in China.
Scrip - February 5, 2026
Update On ADCs: Sales, Deals, Targets And Approvals
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
In Vivo - February 5, 2026
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
In Vivo - February 5, 2026
Chinese AI-Driven Drug Developers Rake In VC/PE Funds
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Scrip - February 5, 2026
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Scrip - February 5, 2026
Estée Lauder Pays Fine For Violating Canadian Law Over Cosmetic PFAS
The Estee Lauder Companies, Inc. pleaded guilty to two counts of violating a Canadian Act that had required it to correct missteps related to selling products containing PFAS.
HBW Insight - February 5, 2026
The Estee Lauder Companies, Inc. pleaded guilty to two counts of violating a Canadian Act that had required it to correct missteps related to selling products containing PFAS.
HBW Insight - February 5, 2026
New York Congressional Delegation Member Slams State’s Age-Restricted Supplement Sales Law
“Dietary Supplement Regulatory Uniformity Act” would prohibit states from adding requirements and rules for supplement manufacturing and sales on top of FDA regulations.
HBW Insight - February 5, 2026
“Dietary Supplement Regulatory Uniformity Act” would prohibit states from adding requirements and rules for supplement manufacturing and sales on top of FDA regulations.
HBW Insight - February 5, 2026
Bristol’s 2026 Revenue Buoyed By Eliquis Ahead Of Ex-US Generic Entries In 2027
The impact of rising demand, Medicare price negotiations under the IRA, Medicaid concessions under its Trump administration drug pricing deal and direct-to-patient sales will combine to boost Eliquis sales this year.
Scrip - February 5, 2026
The impact of rising demand, Medicare price negotiations under the IRA, Medicaid concessions under its Trump administration drug pricing deal and direct-to-patient sales will combine to boost Eliquis sales this year.
Scrip - February 5, 2026
Lilly Takes Incretins Beyond Metabolic Diseases Amid Broader Development Push
The drugmaker highlighted a wide array of development programs in its fourth quarter earnings, including moving tirzepatide into multiple inflammatory conditions.
Scrip - February 5, 2026
The drugmaker highlighted a wide array of development programs in its fourth quarter earnings, including moving tirzepatide into multiple inflammatory conditions.
Scrip - February 5, 2026
In Latest Blow To Novo, Hims & Hers Launches Compounded Wegovy Pill
Novo Nordisk said it will take legal action against mass compounding of the new oral semaglutide formulation by Hims & Hers.
Scrip - February 5, 2026
Novo Nordisk said it will take legal action against mass compounding of the new oral semaglutide formulation by Hims & Hers.
Scrip - February 5, 2026
AstraZeneca’s Precision Oncology Approach Applies To Deal, Portfolio Decisions
Given its already large cancer drug pipeline, EVP of oncology R&D Susan Galbraith spoke with Scrip about how AstraZeneca is making precise choices about deals and development programs.
Scrip - February 5, 2026
Given its already large cancer drug pipeline, EVP of oncology R&D Susan Galbraith spoke with Scrip about how AstraZeneca is making precise choices about deals and development programs.
Scrip - February 5, 2026
Executives On The Move: Lexeo Therapeutics Gets A New CMO From Bristol Myers Squibb
Recent moves in the industry include internal moves at Immunocore, Ipsen and Merck KGaA, plus BioNTech gets a new chief people officer.
Scrip - February 5, 2026
Recent moves in the industry include internal moves at Immunocore, Ipsen and Merck KGaA, plus BioNTech gets a new chief people officer.
Scrip - February 5, 2026
The Hunt For A Monthly Obesity Drug Is Heating Up
Monthly obesity therapies may not have to rival the efficacy of weekly injections if they can be more convenient and help patients stay on treatment longer.
Scrip - February 5, 2026
Monthly obesity therapies may not have to rival the efficacy of weekly injections if they can be more convenient and help patients stay on treatment longer.
Scrip - February 5, 2026
Bayer Buoyant As Asundexian Shows 26% Reduction In Stroke
The co-principal investigator of OCEANIC-STROKE tells Scrip that the oral Factor XIa inhibitor could be paradigm-changing.
Scrip - February 5, 2026
The co-principal investigator of OCEANIC-STROKE tells Scrip that the oral Factor XIa inhibitor could be paradigm-changing.
Scrip - February 5, 2026
Everest Bags APAC Rights To Micot’s First-In-Class Peptide
Everest Medicine obtains selected commercialization rights to first-in-class, Phase III stage bispecific peptide MT1013 from Shanxi Micot Technology at home. A trial for secondary hyperparathyroidism is due to be completed by year-end in China.
Scrip - February 5, 2026
Everest Medicine obtains selected commercialization rights to first-in-class, Phase III stage bispecific peptide MT1013 from Shanxi Micot Technology at home. A trial for secondary hyperparathyroidism is due to be completed by year-end in China.
Scrip - February 5, 2026
Chinese AI-Driven Drug Developers Rake In VC/PE Funds
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Scrip - February 5, 2026
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Scrip - February 5, 2026
J&J Unit Cerenovus Recalls Aneurysm Treatment Systems Following Patient Death
Cerenovus is recalling multiple products from its Cerepak Uniform, Cerepak Heliform and Cerepak Freeform product lines due to a higher-than-expected failure to detach rate. While customers were sent a safety alert in October, the US FDA announced the recall on Feb. 5.
Medtech Insight - February 5, 2026
Cerenovus is recalling multiple products from its Cerepak Uniform, Cerepak Heliform and Cerepak Freeform product lines due to a higher-than-expected failure to detach rate. While customers were sent a safety alert in October, the US FDA announced the recall on Feb. 5.
Medtech Insight - February 5, 2026
Roche Diagnostics Sees China Pricing Headwinds Easing In 2026 As Margins Recover From 2025 Lows
Besides China pricing reforms, Roche continued to face cost pressures linked to investments in new technologies such as CGM and LumiraDx. Tariffs also weighed on performance.
Medtech Insight - February 5, 2026
Besides China pricing reforms, Roche continued to face cost pressures linked to investments in new technologies such as CGM and LumiraDx. Tariffs also weighed on performance.
Medtech Insight - February 5, 2026
CDRH Highlights Harmonization Progress In International Assessment Report
The US FDA has published its annual international harmonization assessment for fiscal 2025, which reports on the device center’s progress in aligning medical device regulations with global standards to improve patient access to safe, innovative technologies.
Medtech Insight - February 5, 2026
The US FDA has published its annual international harmonization assessment for fiscal 2025, which reports on the device center’s progress in aligning medical device regulations with global standards to improve patient access to safe, innovative technologies.
Medtech Insight - February 5, 2026
Execs On The Move: January 26–30, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 5, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 5, 2026
Midi Health Gains Unicorn Status With $100M Funding Round; Adds Serena Ventures, Foresite Capital
Women’s health start-up Midi Health has raised $100m in a Series D financing, led by Goodwater Capital with new investors Foresite Capital and Serena Ventures. Midi, which focuses on women in midlife, said the money will support the next phase of growth.
Medtech Insight - February 5, 2026
Women’s health start-up Midi Health has raised $100m in a Series D financing, led by Goodwater Capital with new investors Foresite Capital and Serena Ventures. Midi, which focuses on women in midlife, said the money will support the next phase of growth.
Medtech Insight - February 5, 2026
Estée Lauder Marks One Year of ‘Beauty Reimagined’ With Expanded Distribution, Innovation
The Estee Lauder Companies' ‘Beauty Reimagined’ initiative is paying off a year after launch, with expanded distribution of brands and ‘breakthrough’ innovations, the firm says during a Feb. 5 fiscal second quarter earnings presentation.
HBW Insight - February 5, 2026
The Estee Lauder Companies' ‘Beauty Reimagined’ initiative is paying off a year after launch, with expanded distribution of brands and ‘breakthrough’ innovations, the firm says during a Feb. 5 fiscal second quarter earnings presentation.
HBW Insight - February 5, 2026
Consumer Health And Wellness Market Outlook: What Trends Will Impact Self-Care In 2026?
In contributed commentary, Susan Levy, SBL Consulting Group founder and principal, discusses likely health and wellness market developments which would reflect a steady shift toward more accessible, consumer-centric models of care complementing traditional healthcare.
HBW Insight - February 5, 2026
In contributed commentary, Susan Levy, SBL Consulting Group founder and principal, discusses likely health and wellness market developments which would reflect a steady shift toward more accessible, consumer-centric models of care complementing traditional healthcare.
HBW Insight - February 5, 2026
Valbiotis Enters Women’s Health Arena With Menopause Supplement
French firm's new supplement combines seven ingredients to offer relief from common menopause symptoms.
HBW Insight - February 5, 2026
French firm's new supplement combines seven ingredients to offer relief from common menopause symptoms.
HBW Insight - February 5, 2026
US FDA’s Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
HBW Insight - February 5, 2026
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
HBW Insight - February 5, 2026
APAC Regulatory Update: Prevention, Access and Digital Integration Define Regional Momentum
Featuring: Prevention?driven reforms in Vietnam; surging demand for OTC and herbal based interventions in China; Singapore updates its health data infrastructure; regional regulatory harmonization across Australia, Singapore and Indonesia; and WHO sets formal direction for TCIM.
HBW Insight - February 5, 2026
Featuring: Prevention?driven reforms in Vietnam; surging demand for OTC and herbal based interventions in China; Singapore updates its health data infrastructure; regional regulatory harmonization across Australia, Singapore and Indonesia; and WHO sets formal direction for TCIM.
HBW Insight - February 5, 2026
Estée Lauder Pays Fine For Violating Canadian Law Over Cosmetic PFAS
The Estee Lauder Companies, Inc. pleaded guilty to two counts of violating a Canadian Act that had required it to correct missteps related to selling products containing PFAS.
HBW Insight - February 5, 2026
The Estee Lauder Companies, Inc. pleaded guilty to two counts of violating a Canadian Act that had required it to correct missteps related to selling products containing PFAS.
HBW Insight - February 5, 2026
New York Congressional Delegation Member Slams State’s Age-Restricted Supplement Sales Law
“Dietary Supplement Regulatory Uniformity Act” would prohibit states from adding requirements and rules for supplement manufacturing and sales on top of FDA regulations.
HBW Insight - February 5, 2026
“Dietary Supplement Regulatory Uniformity Act” would prohibit states from adding requirements and rules for supplement manufacturing and sales on top of FDA regulations.
HBW Insight - February 5, 2026
Strides Pharma: US-Led Global Fund Cut Hurts; Greater Focus On Ex-US Markets
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors.
Generics Bulletin - February 5, 2026
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors.
Generics Bulletin - February 5, 2026
Kashiv Biosciences Expands Latin American Footprint Through Saya Biologics Partnership
A biosimilar collaboration between Kashiv and Saya aims to expand access to affordable supportive oncology therapies in Mexico and 10 additional Central America and Caribbean markets.
Generics Bulletin - February 5, 2026
A biosimilar collaboration between Kashiv and Saya aims to expand access to affordable supportive oncology therapies in Mexico and 10 additional Central America and Caribbean markets.
Generics Bulletin - February 5, 2026
Krka Doubles Down On Vertical Integration With €140m Investment Push
Slovenia’s Krka is ramping up capital spending to expand global manufacturing capacity, betting that industrial scale and supply resilience will drive its next phase of growth.
Generics Bulletin - February 5, 2026
Slovenia’s Krka is ramping up capital spending to expand global manufacturing capacity, betting that industrial scale and supply resilience will drive its next phase of growth.
Generics Bulletin - February 5, 2026
Amgen Benefits From US Biosimilar Monopoly With $700m Sales For Pavblu
Amgen has revealed just how significant its first-mover advantage on biosimilar aflibercept has been in the US, with the firm’s Eylea rival bringing in sales of $700m in 2025 and helping to push Amgen’s annual biosimilars turnover up by more than a third to $3bn.
Generics Bulletin - February 5, 2026
Amgen has revealed just how significant its first-mover advantage on biosimilar aflibercept has been in the US, with the firm’s Eylea rival bringing in sales of $700m in 2025 and helping to push Amgen’s annual biosimilars turnover up by more than a third to $3bn.
Generics Bulletin - February 5, 2026
Update On ADCs: Sales, Deals, Targets And Approvals
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
In Vivo - February 5, 2026
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
In Vivo - February 5, 2026